On February 14, 2013, Hyperion Therapeutics, Inc., or the Company, entered into the Distribution Services Agreement effective as of February 14, 2013, or the Agreement, between the Company and ASD Healthcare, a division of ASD Specialty Healthcare, Inc., or ASD. Pursuant to the Agreement, ASD will be the exclusive reseller of RavictiTM (glycerol phenylbutyrate). If the Company acquires the marketing rights to BUPHENYL ® (sodium phenylbutyrate) and AMMONUL® (sodium phenylacetate and sodium benzoate) and the Company so elects, ASD will also be the exclusive reseller of BUPHENYL and AMMONUL for a period of at least one year. The Agreement expires in two years, unless sooner terminated under the terms of the Agreement, and may be renewed upon the mutual written agreement of the parties.

The above description of the Agreement is a summary only and is qualified in its entirety by reference to the full text of the Agreement, which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. Portions of Exhibit 10.1 have been omitted pursuant to a request for confidential treatment.

(d) Exhibits.

Exhibit
Number                                   Description

10. 1†      Distribution Services Agreement by and between the Company and ASD
            Healthcare, a division of ASD Specialty Healthcare, Inc., dated
            February 14, 2013.

† Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.